Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Golias, Tereza ^a   Papandreou, Ioanna ^b   Sun, Ramon ^b   Kumar, Bhavna ^b   Brown, Nicole V ^b   Swanson, Benjamin J ^b   Pai, Reetesh ^c   Jaitin, Diego ^d   Le, Quynh Thu ^e   Teknos, Theodoros N ^b   Denko, Nicholas C ^b  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE DEHYDROGENASE COMPLEX; TUMOR PROTEIN;

ANIMAL; CELL HYPOXIA; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PYRUVATE DEHYDROGENASE COMPLEX;

EID: 84981288024     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31146     Document Type: Article

References (42)

1. Deberardinis, R. J., Sayed, N., Ditsworth, D., Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Current Opinion in Genetics & Development 18, 54-61, doi: S0959-437X(08)00028-2 (2008).
2. Wijsman, R., Kaanders, J. H., Oyen, W. J., Bussink, J. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging 57, 244-256, doi: R39Y2013N03A0244 (2013).
3. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123, 3664-3671, doi: 67230 (2013).
4. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer 8, 705-713, doi: 10.1038/nrc2468 (2008).
5. Le Floch, R. et al. CD147 subunit of lactate/H + symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA 108, 16663-16668, doi: 1106123108 (2011).
6. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 3, 187-197, doi: S1550-4131(06)00060-X (2006).
7. Kim, J. W., Tchernyshyov, I., Semenza, G. L., Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 3, 177-185, doi: S1550-4131(06)00062-3 (2006).
8. Patel, M. S., Korotchkina, L. G. Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans 34, 217-222, doi: BST20060217 (2006).
9. Lu, C. W., Lin, S. C., Chen, K. F., Lai, Y. Y., Tsai, S. J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283, 28106-28114, doi: M803508200 (2008).
10. Tello, D. et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity. Cell Metabolism 14, 768-779, doi: S1550-4131(11)00394-9 (2011).
11. Zhang, H. et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420, doi: S1535-6108(07)00115-8 (2007).
12. Korotchkina, L. G., Patel, M. S. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J Biol Chem 276, 37223-37229, doi: 10.1074/jbc.M103069200 (2001).
13. Cairns, R. A., Papandreou, I., Sutphin, P. D., Denko, N. C. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104, 9445-9450, doi: 0611662104 (2007).
14. Ryan, H. E., Lo, J., Johnson, R. S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17, 3005-3015, doi: 10.1093/emboj/17.11.3005 (1998).
15. Li, L. et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Research 65, 7249-7258, doi: 65/16/7249 (2005).
16. McFate, T. et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283, 22700-22708, doi: M801765200 (2008).
17. Kumar, B. et al. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther 11, 1988-1998, doi: 1535-7163.MCT-12-0167 (2012).
18. Bradford, C. R. et al. Biomarkers in advanced larynx cancer. Laryngoscope 124, 179-187, doi: 10.1002/lary.24245 (2014).
19. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., Harris, A. L. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 7, 1-6 (2005).
20. Linn, T. C., Pettit, F. H., Reed, L. J. Alpha-keto acid dehydrogenase complexes. X. Regulation of the activity of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. Proc Natl Acad Sci USA 62, 234-241 (1969).
21. Gudi, R., Bowker-Kinley, M. M., Kedishvili, N. Y., Zhao, Y., Popov, K. M. Diversity of the pyruvate dehydrogenase kinase gene family in humans. J Biol Chem 270, 28989-28994 (1995).
22. Fan, J. et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Molecular Cell 53, 534-548, doi: S1097-2765(14)00032-X (2014).
23. Hitosugi, T. et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Molecular Cell 44, 864-877, doi: S1097-2765(11)00891-4 (2011).
24. Chen, D. et al. Characterization and application of monoclonal antibodies against Mycoplasma hyorhinis pyruvate dehydrogenase E1 complex subunit alpha. Appl Microbiol Biotechnol 100, 3587-3597, doi: 10.1007/s00253-015-7263-0 (2016).
25. Sun, R. C., Denko, N. C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metabolism 19, 285-292, doi: S1550-4131(13)00493-2 (2014).
26. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298-302, doi: nature13236 (2014).
27. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 108, 8674-8679, doi: 1016627108 (2011).
28. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388, doi: nature10642 (2012).
29. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384, doi: nature10602 (2012).
30. Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108, 19611-19616, doi: 1117773108 (2011).
31. van den Broek, G. B. et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124, 2643-2650, doi: 10.1002/ijc.24254 (2009).
32. Kunkel, M. et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 43, 796-803, doi: S1368-8375(06)00283-1 (2007).
33. Fan, J. et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell 53, 534-548, doi: 10.1016/j.molcel.2013.12.026 (2014).
34. Li, X. et al. Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Mol Cell 61, 705-719, doi: 10.1016/j.molcel.2016.02.009 (2016).
35. Velpula, K. K., Bhasin, A., Asuthkar, S., Tsung, A. J. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res 73, 7277-7289, doi: 10.1158/0008-5472.CAN-13-1868 (2013).
36. Wigfield, S. M. et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 98, 1975-1984, doi: 10.1038/sj.bjc.6604356 (2008).
37. Hur, H. et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol 42, 44-54, doi: 10.3892/ijo.2012.1687 (2013).
38. Lohneis, P. et al. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Anticancer Res 35, 6329-6334 (2015).
39. Bowker-Kinley, M. M., Davis, W. I., Wu, P., Harris, R. A., Popov, K. M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329 (Pt 1), 191-196 (1998).
40. Shroads, A. L. et al. Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. J Pharmacol Exp Ther 324, 1163-1171, doi: jpet.107.134593 (2008).
41. Morrell, J. A. et al. AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2. Biochem Soc Trans 31, 1168-1170, doi: 10.1042/(2003).
42. Mann, W. R. et al. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors. Biochimica Et Biophysica Acta 1480, 283-292, doi: S0167-4838(00)00079-0 (2000).